CO2017005572A2 - Composiciones anticancerígenas - Google Patents

Composiciones anticancerígenas

Info

Publication number
CO2017005572A2
CO2017005572A2 CONC2017/0005572A CO2017005572A CO2017005572A2 CO 2017005572 A2 CO2017005572 A2 CO 2017005572A2 CO 2017005572 A CO2017005572 A CO 2017005572A CO 2017005572 A2 CO2017005572 A2 CO 2017005572A2
Authority
CO
Colombia
Prior art keywords
prostate cancer
rna
hpmcas
castration
resistant
Prior art date
Application number
CONC2017/0005572A
Other languages
English (en)
Inventor
Dennis Martin Hester
Jason Michael Vaughn
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of CO2017005572A2 publication Critical patent/CO2017005572A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas de ARN-509, que pueden administrarse a un mamífero, particularmente a un ser humano, que sufre una enfermedad o afección relacionada con un receptor de andrógenos (AR), particularmente cáncer, más particularmente cáncer de próstata, que incluye, pero sin limitarse a, cáncer de próstata resistente a castración, cáncer de próstata metastásico resistente a castración, cáncer de próstata metastásico resistente a castración sin previo tratamiento quimioterapéutico, cáncer de próstata sensible a hormona bioquímicamente reincidido, o de alto riesgo, cáncer de próstata no metastásico resistente a castración. En un aspecto, estas formulaciones comprenden una dispersión sólida de ARN-509 y HPMCAS. En un aspecto, la dispersión sólida de ARN-509 y HPMCAS puede obtenerse y particularmente se obtiene por extrusión por fusión de una mezcla que comprende ARN-509 y HPMCAS y opcionalmente posterior molido de dicha mezcla extrudida por fusión. En un aspecto, la dispersión sólida de ARN-509 y HPMCAS puede obtenerse y particularmente se obtiene, mediante el secado por aspersión d
CONC2017/0005572A 2014-12-05 2017-06-05 Composiciones anticancerígenas CO2017005572A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196594 2014-12-05
PCT/US2015/063661 WO2016090098A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Publications (1)

Publication Number Publication Date
CO2017005572A2 true CO2017005572A2 (es) 2017-09-20

Family

ID=52006906

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005572A CO2017005572A2 (es) 2014-12-05 2017-06-05 Composiciones anticancerígenas

Country Status (22)

Country Link
US (2) US20170360754A1 (es)
EP (1) EP3226841A1 (es)
JP (2) JP6937692B2 (es)
KR (2) KR20200141533A (es)
CN (2) CN106999431B (es)
AR (1) AR102926A1 (es)
AU (3) AU2015358490B2 (es)
BR (1) BR112017011788A2 (es)
CA (1) CA2969656A1 (es)
CL (1) CL2017001371A1 (es)
CO (1) CO2017005572A2 (es)
CR (1) CR20170216A (es)
EA (1) EA201791222A1 (es)
IL (2) IL252323B (es)
MA (1) MA41107A (es)
MX (2) MX2017007203A (es)
NZ (2) NZ731963A (es)
PH (1) PH12017500964A1 (es)
SG (1) SG11201704267VA (es)
TW (2) TWI702966B (es)
UA (1) UA120950C2 (es)
WO (1) WO2016090098A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
EP3226843B1 (en) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2020144647A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Pharmaceutical composition comprising apalutamide dispersed in apple sauce
EP3918607A1 (en) 2019-01-30 2021-12-08 Janssen Pharmaceutica NV Methods of treating prostate cancer based on molecular subtypes
AU2020215176A1 (en) 2019-01-30 2021-08-05 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide
CA3160121A1 (en) 2019-11-04 2021-05-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023122842A1 (es) * 2021-12-31 2023-07-06 Gador Limitada Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
MXPA03011933A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados.
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
KR100758045B1 (ko) * 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
EP2656842B1 (en) * 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
TWI532732B (zh) 2012-06-07 2016-05-11 亞拉岡製藥公司 雄性激素受體調節劑之晶型
WO2014031422A1 (en) * 2012-08-24 2014-02-27 Dow Global Technologies Llc Novel hydroxyalkyl methyl cellulose acetate succinates
CN109897004A (zh) * 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
EA030128B1 (ru) * 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
BR112016002970A2 (pt) * 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
EA201891397A1 (ru) * 2014-02-05 2019-03-29 Лек Фармасьютикалз Д.Д. Твердые фармацевтические композиции антагонистов рецепторов андрогенов
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses

Also Published As

Publication number Publication date
PH12017500964A1 (en) 2017-10-18
NZ731963A (en) 2024-03-22
SG11201704267VA (en) 2017-06-29
IL252323A0 (en) 2017-07-31
KR20170086656A (ko) 2017-07-26
KR20200141533A (ko) 2020-12-18
AU2021201979B2 (en) 2023-02-02
TWI754258B (zh) 2022-02-01
AU2023202710A1 (en) 2023-05-18
US20170360754A1 (en) 2017-12-21
AU2015358490A1 (en) 2017-06-08
MX2017007203A (es) 2017-08-28
BR112017011788A2 (pt) 2017-12-26
CL2017001371A1 (es) 2018-01-05
TW201630592A (zh) 2016-09-01
NZ770528A (en) 2024-03-22
WO2016090098A1 (en) 2016-06-09
TWI702966B (zh) 2020-09-01
AR102926A1 (es) 2017-04-05
TW202031248A (zh) 2020-09-01
KR102348320B1 (ko) 2022-01-10
US20230233529A1 (en) 2023-07-27
CR20170216A (es) 2017-08-30
MA41107A (fr) 2017-10-10
IL279833B (en) 2022-03-01
CN114886852A (zh) 2022-08-12
UA120950C2 (uk) 2020-03-10
JP2020143069A (ja) 2020-09-10
CN106999431A (zh) 2017-08-01
JP6937692B2 (ja) 2021-09-22
CA2969656A1 (en) 2016-06-09
IL252323B (en) 2021-04-29
JP2017536398A (ja) 2017-12-07
AU2015358490B2 (en) 2021-04-08
CN106999431B (zh) 2022-03-04
EA201791222A1 (ru) 2017-09-29
EP3226841A1 (en) 2017-10-11
IL279833A (en) 2021-01-31
JP7174006B2 (ja) 2022-11-17
MX2021013965A (es) 2022-01-04
AU2021201979A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CO2017005572A2 (es) Composiciones anticancerígenas
CO2017005574A2 (es) Composiciones anticancerígenas que comprenden 4-[7-(6-ciano-5- trifluorometilpiridin-3-ilo)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-ilo]-2-fluoro-nmetilbenzamida, un copolímero de poli(met)acrilato y hpmcas
NI201700069A (es) Composiciones anticancerosas
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
PH12015501737B1 (en) Androgen receptor modulators and uses thereof
MA39906A (fr) Polythérapies pour le traitement du cancer
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
NZ749218A (en) Androgen receptor modulator and uses thereof
EA201792520A3 (ru) Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
EA201891397A1 (ru) Твердые фармацевтические композиции антагонистов рецепторов андрогенов
PH12019502692A1 (en) Anti-cancer combination therapy
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
NI201800127A (es) Composiciones antineoplásicas
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.